NAS
VRDN icon

Nykredit A/S’s Viridian Therapeutics VRDN Stock Holding History

Nykredit A/S’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.3K Buy
+1,268
New +$20.4K ﹤0.01% 1694

Other funds holding VRDN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Nykredit A/S's VRDN Position: Q2 2026 in Review

Nykredit A/S opened a new position in Viridian Therapeutics (VRDN) in Q2 2026: 1,268 shares worth $23.3K. The stake represents ﹤0.01% of the portfolio and ranks #1694 among its holdings.

132 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Nykredit A/S held 1,268 shares of Viridian Therapeutics worth $23.3K as of Q2 2026.
  • Viridian Therapeutics was a new Nykredit A/S position in Q2 2026.
  • Viridian Therapeutics made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #1694 holding.
  • 132 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.